World Pharma News Digest - 12.10.2009

0 views
Skip to first unread message

Ruslan David

unread,
Oct 12, 2009, 4:44:01 AM10/12/09
to worldph...@googlegroups.com
European Medicines Agency implements internal reorganisation 
The European Medicines Agency has begun implementing a series of changes to its internal organisation aimed at improving the functioning of the Agency and the way in which it delivers its core tasks. The changes will be introduced gradually from September to December 2009. 
Read more... 
http://www.worldpharmanews.com/content/view/968/1/
 
Health 2.0 on the Rise - 35% of U.S. Adults Use Social Media for Medical Information 
About 35% of the U.S. adult population uses social media for health and medical purposes in 2009, according to pharmaceutical and healthcare market research company Manhattan Research's Cybercitizen Healthâ„¢ v9.0. These 80 million Health 2.0 Consumers create or consumer content on health blogs, message boards, chat rooms, health social networks and health communities, and patient testimonials. 
Read more... 
http://www.worldpharmanews.com/content/view/967/1/
 
FDA Advisory Committee Recommends Approval of Pfizer's Selzentry 
Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration's (FDA) Antiviral Drugs Advisory Committee voted (10 to 4) to recommend the approval of Selzentry® (maraviroc) tablets for use in treatment-naïve adult patients with CCR5-tropic HIV-1 virus as part of combination therapy. 
Read more... 
http://www.worldpharmanews.com/content/view/966/1/
 
Access to HIV medication 
Boehringer Ingelheim has repeatedly and clearly stated that patents must not prevent access from life-saving drugs for HIV patients living in resource limited settings. In line with this and in order to accelerate access to anti-retroviral medicines, the company has initiated non-assert declarations in May 2007, well before the idea of the UNITAID patent pool was conceived. 
Read more... 
http://www.worldpharmanews.com/content/view/965/1/
 
GSK expands presence in China through strategic cooperation 
GlaxoSmithKline (GSK) and Jiangsu Walvax Biotech Company (Walvax) have announced a cooperation agreement to form a long-term Joint Venture (JV) to develop and manufacture paediatric vaccines for use in China. The JV will produce vaccines for measles, mumps, and rubella (MMR) (Priorixâ„¢) and potentially other paediatric vaccines. GSK will also transfer the technology to enable the JV to manufacture the vaccines locally over time. 
Read more... 
http://www.worldpharmanews.com/content/view/964/1/
 
FDA Marks 100th HIV/AIDS Drug Authorized for Purchase Under PEPFAR 
The U.S. Department of Health and Human Services (HHS) marked the recent approval of the 100th antiretroviral drug in association with the President's Emergency Plan for AIDS Relief (PEPFAR), aimed at the prevention, treatment, and care of people infected with and affected by HIV/AIDS worldwide. 
Read more... 
http://www.worldpharmanews.com/content/view/963/1/
 
Sandoz launches somatropin, the first-ever Japanese biosimilar 
Sandoz announced the launch of its recombinant human growth hormone somatropin in Japan, the first-ever biosimilar to be approved and launched on the world's second largest pharmaceutical market. 
Read more... 
http://www.worldpharmanews.com/content/view/962/1/
 
Physician Smartphone Adoption Rate to Reach 81% in 2012 
Physician smartphone adoption rates will experience significant growth over the next few years. Currently, 64% of U.S. physicians own smartphones, but this will increase to 81% penetration in 2012, according to the latest physician report from pharmaceutical and healthcare company Manhattan Research. "Physicians in 2012: The Outlook for On Demand, Mobile, and Social Digital Media", is part of the company's Taking the Pulse® market research and strategic advisory service. 
Read more... 
http://www.worldpharmanews.com/content/view/961/1/
 
PharmaNews.eu / Latest News
 
 
 
Panenza® and Humenza® Influenza A(H1N1) Vaccines Demonstrate Robust Immune Response After One Dose
http://www.pharmanews.eu/sanofi-aventis/345-panenzar-and-humenzar-influenza-ah1n1-vaccines-demonstrate-robust-immune-response-after-one-dose
 
Bayer Schering Pharma collaborates with AC Immune in the field of Alzheimer's disease
http://www.pharmanews.eu/bayer/344-bayer-schering-pharma-collaborates-with-ac-immune-in-the-field-of-alzheimers-disease
 
 
 
ONGLYZA (saxagliptin) Receives Marketing Authorisation in Europe for the Treatment of Type 2 Diabete
http://www.pharmanews.eu/astrazeneca/341-onglyza-saxagliptin-receives-marketing-authorisation-in-europe-for-the-treatment-of-type-2-diabete
 
European Medicines Agency recommends authorisation of additional vaccine for influenza pandemic (H1N1) 2009
http://www.pharmanews.eu/emea/340-european-medicines-agency-recommends-authorisation-of-additional-vaccine-for-influenza-pandemic-h1n1-2009
 
 
Herceptin provides impressive survival benefit for patients with high levels of HER2 in their stomach cancer
http://www.pharmanews.eu/roche/338-herceptin-provides-impressive-survival-benefit-for-patients-with-high-levels-of-her2-in-their-stomach-cancer
 
With best regards,
Ruslan David, MD
Administrator/Editor
 
 
PS:
Subscribe to World Pharma News alerts by Email (a free service delivered by Google) -
http://feedburner.google.com/fb/a/mailverify?uri=worldpharmanews&loc=en_US

Subscribe to PharmaNews.eu alerts by Email (a free service delivered by Google) -
http://feedburner.google.com/fb/a/mailverify?uri=pharmanewseu&loc=en_US

Reply all
Reply to author
Forward
0 new messages